Showing 9,521 - 9,540 results of 18,438 for search 'significantly ((((((we decrease) OR (largest decrease))) OR (mean decrease))) OR (a decrease))', query time: 0.60s Refine Results
  1. 9521

    DataSheet2_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

    Published 2024
    “…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”
  2. 9522

    DataSheet3_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

    Published 2024
    “…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”
  3. 9523
  4. 9524

    Image 1_Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review.jpeg by Xin Fei (20466992)

    Published 2024
    “…The patient was then administered a combination of anlotinib and tislelizumab. After treatment, the patient’s symptoms were controlled, tumor marker levels decreased, and imaging showed significant improvement. …”
  5. 9525

    Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  6. 9526

    Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  7. 9527

    Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  8. 9528

    Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  9. 9529

    Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  10. 9530

    Supplementary Material for: Delayed Onset of Central Serous Chorioretinopathy (CSCR) following corticosteroid treatment for Giant Cell Arteritis (GCA): A Case Report by figshare admin karger (2628495)

    Published 2025
    “…Although the association between CSCR and corticosteroids is well established, its occurrence in patients diagnosed with GCA remains rarely reported in literature. Case Presentation: We present a case of a 71-year-old man who developed CSCR following six months of corticosteroid treatment for GCA. …”
  11. 9531

    Table 3_Global, regional, and national burden of acute hepatitis (1990–2021): a systematic analysis of the global burden of disease in 2021.xlsx by Zhixun Bai (14021787)

    Published 2025
    “…Background<p>Acute viral hepatitis (AVH) remains a global health concern, with significant variations in incidence, mortality, and DALYs across different regions, age groups, genders, and socioeconomic levels. …”
  12. 9532

    Table 2_Global, regional, and national burden of acute hepatitis (1990–2021): a systematic analysis of the global burden of disease in 2021.xlsx by Zhixun Bai (14021787)

    Published 2025
    “…Background<p>Acute viral hepatitis (AVH) remains a global health concern, with significant variations in incidence, mortality, and DALYs across different regions, age groups, genders, and socioeconomic levels. …”
  13. 9533

    Table 1_Global, regional, and national burden of acute hepatitis (1990–2021): a systematic analysis of the global burden of disease in 2021.docx by Zhixun Bai (14021787)

    Published 2025
    “…Background<p>Acute viral hepatitis (AVH) remains a global health concern, with significant variations in incidence, mortality, and DALYs across different regions, age groups, genders, and socioeconomic levels. …”
  14. 9534

    Data Sheet 1_Impact of the SARS-COV-2 pandemic on access to health services in Angola: a focus on diagnosis and treatment services for tuberculosis.docx by Susanna Caminada (16789893)

    Published 2025
    “…</p>Results<p>There was a significant decline in access to TB services during the pandemic, with a substantial decrease in reported cases (−15.5% in 2020; −18.3% in 2021) and treatment rate (from 86% in 2019 to 68% in 2020), an increase in multidrug-resistant-TB (from 0.2% in 2018 to 2.1% in 2022) and TB/HIV co-infections (from 6% in 2018 to 8.8% in 2021). …”
  15. 9535

    <b>Keystone taxa and microbial network complexity, rather than diversity, sustain soil multifunctionality along an elevational gradient in a subtropical karst mountain</b> by Weixue Luo (6070040)

    Published 2025
    “…</a>Moreover, annual mean temperature and soil pH significantly influenced microbial characteristics, which in turn affected soil EMF. …”
  16. 9536

    Bacterial strains used in this study. by Nobuo Fuke (22190368)

    Published 2025
    “…<i><i>elegans</i></i>. We cultured <i><i>Escherichia coli</i></i> OP50 (the standard <i><i>C</i></i>. …”
  17. 9537

    Supplementary file 1_Global burden of pulmonary sarcoidosis from 1990 to 2021: a comprehensive analysis based on the GBD 2021 study.xlsx by Jinming Cao (7837883)

    Published 2025
    “…Background and objective<p>Pulmonary sarcoidosis is a chronic respiratory disease with a growing global burden. …”
  18. 9538

    Supplementary file 4_Global burden of pulmonary sarcoidosis from 1990 to 2021: a comprehensive analysis based on the GBD 2021 study.xlsx by Jinming Cao (7837883)

    Published 2025
    “…Background and objective<p>Pulmonary sarcoidosis is a chronic respiratory disease with a growing global burden. …”
  19. 9539

    Table 1_Mental symptoms in post-COVID syndrome and post-COVID-19 vaccination syndrome: results of a representative population survey.docx by Andreas Czaplicki (21978866)

    Published 2025
    “…Although symptom profiles may overlap, comparative epidemiological data from the general population are limited.</p>Methods<p>We conducted a representative online survey of 4,632 adults in Germany and investigated mental symptoms associated with PCS and PCVS, including fatigue, cognitive problems, sleep disturbances, impaired performance and depressed mood. …”
  20. 9540

    Supplementary file 2_Global burden of pulmonary sarcoidosis from 1990 to 2021: a comprehensive analysis based on the GBD 2021 study.xlsx by Jinming Cao (7837883)

    Published 2025
    “…Background and objective<p>Pulmonary sarcoidosis is a chronic respiratory disease with a growing global burden. …”